BioSpace News Archive

Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and year ended March 31, 2023.

Clover Biopharmaceuticals, Ltd. announced that it has established a commercial partnership with Keyuan Xinhai Medical Products Trading Co. Ltd., a leading pharmaceutical import and distribution company in China, as it prepares for the commercial launch of AdimFlu-S, the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China.

Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced the pricing of its underwritten public offering of 11,125,000 shares of its common stock at a price to the public of $11.75 per share.

Allgenesis Biotherapeutics Inc., a clinical-stage specialty pharmaceutical company focused on developing novel ophthalmic drugs, announces exciting preliminary data from the two initial cohorts of the on-going AG-77305 FIH Phase 2a clinical trial for the treatment of Diabetic Macular Edema (DME) in the US.

Camurus announces that the US Food and Drug Administration has approved Brixadi™ extended release injection for subcutaneous use, a weekly and monthly medication for the treatment of moderate to severe opioid use disorder, in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with a daily buprenorphine product.